Evidence map›Paper›PMID 40176764›Full record

ArticleHaematologica2025

Long-term kidney complications in childhood leukemia survivors: a study from the Childhood and Adolescent Leukemia (LEA) project.

Carine Domenech, Paul Saultier, Zeinab Hamidou, Marie-Dominique Tabone, Marlène Pasquet, Virginie Gandemer, Stéphane Ducassou, Marilyne Poirée, Dominique Plantaz, Jean-Hugues Dalle and 11 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01756599 (Multi-centre Prospective Cohort of Childhood Leukaemia), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01756599 naunknown statusnot on this map

Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence - LEA

TypeinterventionalSponsorAssistance Publique Hopitaux De MarseilleRan2012 to 2023Enrolled2,900ConditionsLeukaemia During Childhood or AdolescenceArmsblood samples
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Carine DomenechInstitute of Hematology and Pediatric Oncology, Hospices Civils of Lyon, Lyon 1 University, Lyon, France; Medical school Lyon Sud, Claude Bernard University Lyon 1, Lyon. carine.halfondomenech@ihope.fr.
Paul SaultierDepartment of Pediatric Hematology, Immunology and Oncology, Aix-Marseille University and La Timone Children's Hospital, Marseille.
Zeinab HamidouDepartment of Public Health -EA 3279 Research Unit, University Hospital Marseille, Aix-Marseille University.
Marie-Dominique TaboneDepartment of Pediatric Hematology, Immunology and Oncology, A. Trousseau Hospital, Sorbonne University, AP-HP, Paris.
Marlène PasquetDepartment of Pediatric Hematology-Oncology, CHU-Hôpital Purpan, Toulouse.
Virginie GandemerPediatric Hematology and Oncology department, University Hospital, Rennes.
Stéphane DucassouDepartment of Pediatric Hematology and Oncology, University Hospital of Bordeaux.
Marilyne PoiréePediatric Hematology and Oncology department, University Hospital L'Archet, Nice.
Dominique PlantazDepartment of Pediatric Hematology-Oncology, University Hospital of Grenoble.
Jean-Hugues DalleDepartment of Pediatric Hematology and Immatology, Robert Debré Hospital, GHU AP-HP Nord Université Paris Cité, Paris.
Pascal ChastagnerDepartment of Pediatric Onco-Hematology, Hôpital d'Enfants de Brabois, Vandoeuvre-les-Nancy.
Sandrine ThouveninDepartment of Pediatric Hematology-Oncology, Hospital University, St Etienne.
Justyna KanoldDepartment of Pediatric Hematology and Oncology, University Hospital of Clermont-Ferrand.
Alexandre TheronPediatric Hematology and Oncology department, University Hospital, Montpellier.
Isabelle PellierPediatric Hematology-Oncology Unit, CHU Angers, Angers.
Yves ReguerresPediatric Hematology-Oncology Unit, CHU La Reunion,.
André BaruchelDepartment of Pediatric Hematology and Immatology, Robert Debré Hospital, GHU AP-HP Nord Université Paris Cité, Paris.
Pascal AuquierDepartment of Public Health -EA 3279 Research Unit, University Hospital Marseille, Aix-Marseille University.
Justine BacchettaCentre de Référence des Maladies Rénales Rares, Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques, Hospices Civils de Lyon, Université Lyon 1, Lyon, France; Medical school Lyon Est, Claude Bernard University Lyon 1, Lyon, France; Service de Néphrologie Rhumatologie et Dermatologie Pédiatrique, Centre de Référence des Maladies Rénales Rares, filière maladies rares ORKID and ERKNet. Hospices Civils de Lyon, Bron.
Gérard MichelDepartment of Pediatric Hematology, Immunology and Oncology, Aix-Marseille University and La Timone Children's Hospital, Marseille, France; Department of Public Health -EA 3279 Research Unit, University Hospital Marseille, Aix-Marseille University.
Laurence Derain-DubourgMedical school Lyon Est, Claude Bernard University Lyon 1, Lyon, France; Néphrologie, Dialyse, Hypertension et Exploration Fonctionnelle Rénale, Groupement Hospitalier Edouard-Herriot, Hospices Civils de Lyon, Lyon, France; University of Lyon 1; CNRS UMR 5305, Lyon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute leukemias represent the first cause of cancer in children. Their prognosis has improved significantly due to remarkable advances in therapeutic management, despite the risk of long-term consequences, especially for patients who underwent allogenic hematopoietic stem cell transplantation (aHSCT). Through the Leukemia in Children and Adolescents (LEA) long-term follow-up cohort (clinicaltrials gov. Identifier: NCT01756599), we conducted a French national multicenter prospective study on the occurrence and risk factors of chronic kidney disease (CKD), differentiating glomerular and tubular dysfunctions, corresponding to the NephroLEA project. Among the 1,676 patients included, the median age at evaluation was 15.8 (interquartile range [IQR], 11.3-20.5) years, with a median follow-up of 9.2 (IQR, 5.8-13.9) years. aHSCT was performed on 343 (20.6%) patients, half of whom have undergone the procedure after achieving second or greater remission. A higher percentage of children among transplanted patients had diastolic and systolic blood pressure above the 95th, with 13.7% versus 5.2% (P=3x10-3) and 15% versus 6.5% (P=9x10-2), respectively. A total of 187 patients (11.1%) had a mild CKD (i.e., eGFR between 75 and 90 mL/min/1.73 m2), while 3% (N=50) exhibited mild to severe CKD (eGFR <75 mL/min/1.73 m2). Notably, no patient reached kidney failure. Twenty-one patients (1.3%) had decreased glomerular filtration rate associated with tubular impairment. The principal risk factors for developing CKD were aHSCT and leukemia relapse. In conclusion, CKD represents a long-term risk for patients who relapsed and/or underwent aHSCT. These patients could benefit from nephroprotection advice to further improve their long-term outcomes, which is becoming a public health issue.

Indexed as

Cancer SurvivorsHematopoietic Stem Cell TransplantationLeukemiaRenal Insufficiency, ChronicAdolescentAdultChildChild, PreschoolFemaleFollow-Up StudiesFranceGlomerular Filtration RateHumansMaleProspective StudiesRisk Factors

Identifiers

PMID40176764
PMCPMC12399945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.